Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||PBRM1 inact mut|
|Indication/Tumor Type||clear cell renal cell carcinoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PBRM1 inact mut||clear cell renal cell carcinoma||sensitive||Nivolumab||Clinical Study - Cohort||Actionable||In a clinical study, renal clear cell carcinoma patients harboring PBRM1 loss-of-function mutations demonstrated improved response to immune checkpoint therapies including Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), and Tecentriq (atezolizumab), potentially due to the distinct expression profile of immune-related genes in these patients (PMID: 29301960).||29301960|
|PubMed Id||Reference Title||Details|
|(29301960)||Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.||Full reference...|